Indeed, several different murine models have confirmed that either genetic or chemical modulation of CD40 signaling can modify the severity of autoimmune thyroiditis or thyroid autoantibody production (49, 55, 56), establishing CD40 as a potential therapeutic target in the treatment of Graves’ hyperthyroidism. The gene discussed is CD40; the disease is thyroid gland disorder.